3245-45-2

Basic information

• Product Name: 1-(2-BROMOETHOXY)-3-METHOXYBENZENE
• Synonyms: CHEMBRDG-BB 5471033;1-(2-BROMOETHOXY)-3-METHOXYBENZENE;AKOS BC-2660;TIMTEC-BB SBB011620;3-(2-Bromoethoxy)anisole;1-(2-bromoethoxy)-3-methoxybenzene(SALTDATA: FREE)
• CAS NO: 3245-45-2
• Molecular Formula: C₉H₁₁BrO₂
• Molecular Weight: 231.08644
• Mol File: 3245-45-2.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 84/0.023mm
• Flash Point: 128.3 °C
• Appearance: /
• Density: 1.38 g/cm³
• Vapor Pressure: 0.00373mmHg at 25°C
• Refractive Index: 1.534
• CAS DataBase Reference: 1-(2-BROMOETHOXY)-3-METHOXYBENZENE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-BROMOETHOXY)-3-METHOXYBENZENE(3245-45-2)
• EPA Substance Registry System: 1-(2-BROMOETHOXY)-3-METHOXYBENZENE(3245-45-2)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 3245-45-2(Hazardous Substances Data)

Usage

General Description

1-(2-bromoethoxy)-3-methoxybenzene is a chemical compound with the molecular formula C9H11BrO2. It is a clear, colorless liquid that is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. The compound is known for its high reactivity, which makes it useful for a wide range of applications in organic chemistry. It is also used as a solvent in chemical reactions and as a reagent in the production of various organic compounds. Additionally, 1-(2-bromoethoxy)-3-methoxybenzene is considered to be a potential environmental hazard and should be handled with caution due to its toxic and flammable properties.

InChI:InChI=1/C9H11BrO2/c1-11-8-3-2-4-9(7-8)12-6-5-10/h2-4,7H,5-6H2,1H3

Upstream product

• 150-76-5 4-methoxy-phenol 
• 34114-37-9 2-(5-methoxyphenoxy)-ethanol 
• 150-19-6 O-methylresorcine 
• 106-93-4 ethylene dibromide 

Downstream Products

• 92099-85-9 [2-(3-methoxy-phenoxy)-ethyl]-dimethyl-amine 
• 120998-52-9 [2-(3-methoxy-phenoxy)-ethyl]-methyl-amine 
• 6487-86-1 2-(3-methoxyphenoxy)ethanamine 
• 1446339-23-6 (S)-3-{1-[2-(3-methoxyphenoxy)ethyl]piperidin-2-yl}pyridine oxalate 
• 1422463-13-5 2-(2-((2-(3-methoxyphenoxy)ethyl)amino)ethyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione 
• 1394161-99-9 1-(2-(3-methoxyphenoxy)ethyl)-4-nitro-1H-pyrazole 
• 1394162-00-5 1-[2-(3-methoxy-phenoxy)-ethyl]-1H-pyrazol-4-ylamine 
• 6488-05-7 2-[2-(3-methoxyphenoxy)ethyl]-1H-isoindole-1,3(2H)-dione 
• 1160121-90-3 1-[3-(2-(3-methoxyphenoxy)ethoxy)propyl]azepane 
• 1160121-87-8 1-[3-(2-(3-methoxyphenoxy)ethoxy)propyl]-4-methylpiperidine 
• 1160121-84-5 1-[3-(2-(3-methoxyphenoxy)ethoxy)propyl]-3-methylpiperidine 
• 98863-59-3 [2-(3-Methoxy-phenoxy)-ethyl]-dimethyl-(4-nitro-benzyl)-ammonium; chloride 
• 98844-74-7 (4-Chloro-benzyl)-[2-(3-methoxy-phenoxy)-ethyl]-dimethyl-ammonium; chloride 
• 98863-69-5 (2-Chloro-benzyl)-[2-(3-methoxy-phenoxy)-ethyl]-dimethyl-ammonium; chloride 

Relevant articles and documents

Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective D3 Dopamine Receptor Agonist

To identify novel D3 dopamine receptor (D3R) agonists, we conducted a high-throughput screen using a β-arrestin recruitment assay. Counterscreening of the hit compounds provided an assessment of their selectivity, efficacy, and potency. The most promising scaffold was optimized through medicinal chemistry resulting in enhanced potency and selectivity. The optimized compound, ML417 (20), potently promotes D3R-mediated β-arrestin translocation, G protein activation, and ERK1/2 phosphorylation (pERK) while lacking activity at other dopamine receptors. Screening of ML417 against multiple G protein-coupled receptors revealed exceptional global selectivity. Molecular modeling suggests that ML417 interacts with the D3R in a unique manner, possibly explaining its remarkable selectivity. ML417 was also found to protect against neurodegeneration of dopaminergic neurons derived from iPSCs. Together with promising pharmacokinetics and toxicology profiles, these results suggest that ML417 is a novel and uniquely selective D3R agonist that may serve as both a research tool and a therapeutic lead for the treatment of neuropsychiatric disorders.

DOPAMINE D2 RECEPTOR LIGANDS

The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopaminergic activity. The present invention relates to novel compounds that modulate dopamine D2 receptors. In particular, compounds of the present invention show functional selectivity at the dopamine D2 receptors and exhibit selectivity downstream of the D2 receptors, on the 0- arrestin pathway and/or on the cAMP pathway.

Development of unsymmetrical dyads as potent noncarbohydrate-based inhibitors against human β-N-acetyl-D-hexosaminidase

Human β-N-acetyl-D-hexosaminidase has gained much attention due to its roles in several pathological processes and been considered as potential targets for disease therapy. A novel and efficient skeleton, which was an unsymmetrical dyad containing naphthalimide and methoxyphenyl moieties with an alkylamine spacer linkage as a noncarbohydrate-based inhibitor, was synthesized, and the activities were valuated against human β-N-acetyl-D- hexosaminidase. The most potent inhibitor exhibits high inhibitory activity with Ki values of 0.63 μM. The straightforward synthetic manners of these unsymmetrical dyads and understanding of the binding model could be advantageous for further structure optimization and development of new therapeutic agents for Hex-related diseases.